$6.5M Amylyx Pharmaceuticals Securities Class Action Settlement
Amylyx Pharmaceuticals has agreed to pay $6.5 million to settle a securities class action. If you purchased Amylyx Pharmaceuticals (NASDAQ: AMLX) common stock between November 11, 2022 and November 8, 2023, you may be entitled to a cash payment based on your recognized stock losses.
Do I Qualify?
You may be eligible if:
- Investors who purchased Amylyx Pharmaceuticals (NASDAQ: AMLX) common stock between November 11, 2022 and November 8, 2023
- You provide brokerage records showing purchase and sale dates and prices
- You submit a valid claim before August 31, 2026
Brokerage records are required. You must provide records showing your purchase dates, prices, and any sales during the class period.
File your claim through the official settlement website.
File Your Claim →What Happened?
Amylyx Pharmaceuticals, the maker of Relyvrio — an ALS treatment drug — was sued by shareholders who alleged the company made misleading statements about the drug's clinical effectiveness. The lawsuit alleged that Amylyx concealed negative data about Relyvrio's performance in clinical trials while continuing to promote the drug and raise capital from investors.
When the company disclosed that a confirmatory clinical trial had failed to demonstrate the drug's effectiveness, Amylyx announced it would withdraw Relyvrio from the market — a devastating outcome for ALS patients and investors alike. The company agreed to pay $6.5 million to settle the securities class action.
How Much Will I Actually Get?
Payments are calculated based on your recognized loss. Brokerage records are required. Deadline is August 31, 2026.
Last updated: June 17, 2026 | Information verified from court records and official settlement documents.